Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in metastatic pheochromocytoma or paraganglioma
NCT03946527Phase 2Active, not recruiting
- Start
- Jun 2019
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lanreotide in Paraganglioma (PGL), pheochromocytoma. Started Jun 2019; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
Paraganglioma (PGL)pheochromocytoma
Beyond the preview
Go deeper on NCT03946527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946527.